TAO Synergies (TAOX) Non-cash Items (2019 - 2026)
TAO Synergies' (TAOX) quarterly Non-cash Items came in at $8.4 million in Q2 2026, down 49.76% on a YoY basis from $16.8 million in Q2 2025, and up 241.88% quarter-over-quarter from -$5.9 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Non-cash Items (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Non-cash Items for 8 consecutive years, with $8.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-cash Items fell 49.76% year-over-year to $8.4 million; the trailing twelve-month figure through Jun 2026 stood at $10.4 million (down 55.49% YoY), and the FY2025 full-year result was $22.3 million, up 183.37% from the prior year.
- Non-cash Items improved to $8.4 million in Q2 2026 per TAOX's latest filing, from -$5.9 million in the prior quarter.
- Across five years, Non-cash Items topped out at $16.8 million in Q2 2025 and bottomed at -$7.3 million in Q4 2022.
- Historically, Non-cash Items has averaged $1.6 million across 5 years, with a median of $514006.5 in 2022.
- The widest YoY moves for Non-cash Items: up 6352.46% in 2024, down 10273.07% in 2024.
- Over 5 years, Non-cash Items stood at -$7.3 million in 2022, then jumped by 99.04% to -$70031.0 in 2023, then soared by 6352.46% to $4.4 million in 2024, then grew by 19.5% to $5.2 million in 2025, then jumped by 60.99% to $8.4 million in 2026.
- According to Business Quant data, Non-cash Items over the past three periods registered $8.4 million, -$5.9 million, and $5.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 210.97 Bn | 196.98 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.98 Bn | 177.80 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.09 Bn | 124.24 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.57 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.71 Bn | 56.53 Bn | 1.37 Bn |
| 6 | Moderna | 54.60 Bn | 49.46 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.02 Bn | 30.71 Bn | 992.69 Mn |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.76 Bn | 29.76 Bn | 1.16 Mn |
| 10 | TAO Synergies | 30.86 Mn | 30.86 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.42 Mn |
| Mar 31, 2026 | -5.94 Mn |
| Dec 31, 2025 | 5.23 Mn |
| Sep 30, 2025 | 2.73 Mn |
| Jun 30, 2025 | 16.77 Mn |
| Mar 31, 2025 | -2.39 Mn |
| Dec 31, 2024 | 4.38 Mn |
| Sep 30, 2024 | 4.71 Mn |
| Jun 30, 2024 | 419,775.00 |
| Mar 31, 2024 | -1.62 Mn |
| Dec 31, 2023 | -70,031.00 |
| Sep 30, 2023 | -1.94 Mn |
| Jun 30, 2023 | 2.85 Mn |
| Mar 31, 2023 | 15,972.00 |
| Dec 31, 2022 | -7.27 Mn |
| Sep 30, 2022 | 608,238.00 |
| Jun 30, 2022 | 1.23 Mn |
| Mar 31, 2022 | -207,484.00 |
| Dec 31, 2021 | 2.19 Mn |
| Sep 30, 2021 | 1.85 Mn |